- Home
- DAVE vs VCYT Comparison
DAVE vs VCYT Comparison
Compare DAVE & VCYT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DAVE | VCYT |
|---|---|---|
| Founded | 2017 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.9B |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | DAVE | VCYT |
|---|---|---|
| Price | $184.05 | $41.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 8 |
| Target Price | ★ $282.17 | $46.00 |
| AVG Volume (30 Days) | 475.4K | ★ 670.0K |
| Earning Date | 03-02-2026 | 02-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 224.46 | N/A |
| EPS | ★ 10.12 | 0.38 |
| Revenue | $491,301,000.00 | ★ $495,141,000.00 |
| Revenue This Year | $56.88 | $16.46 |
| Revenue Next Year | $18.07 | $11.37 |
| P/E Ratio | ★ $19.17 | $109.27 |
| Revenue Growth | ★ 53.84 | 16.41 |
| 52 Week Low | $65.46 | $22.61 |
| 52 Week High | $286.45 | $50.71 |
Technical Indicators
Market Signals| Indicator | DAVE | VCYT |
|---|---|---|
| Relative Strength Index (RSI) | 35.50 | 44.88 |
| Support Level | $179.00 | $40.29 |
| Resistance Level | $201.07 | $44.59 |
| Average True Range (ATR) | 14.79 | 1.69 |
| MACD | -5.13 | -0.27 |
| Stochastic Oscillator | 9.24 | 20.42 |
Price Performance
Historical ComparisonAbout DAVE Dave Inc.
Dave Inc is a financial services company. It is engaged in offering banking app that offers its customers banking, financial insights, overdraft protection, building credit and finding side gigs.
About VCYT Veracyte Inc.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.